Search Results for: THERAPEUTIC FOCUS Targeted Payload Therapies
Articles
THERAPEUTIC FOCUS - Targeted Payload Therapies Radiate Potential to Attack Various Cancers January 8, 2015
Kaushik J. Dave, PhD, MBA, and Dragan Cicic, MD, MBA, indicate that alpha-particle emitters, such as bismuth-213 or actinium-225, may be more effective and efficient at killing cancerous cells not currently treated with radiation while simultaneously decreasing nonspecific cytotoxic effects.
Lonza and Engitix Announce License Agreement to Advance Targeted ADC Development July 21, 2026
Basel, Switzerland, and London, UK – Lonza, a contract development and manufacturing organization (CDMO), and Engitix, a global leader in...Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases June 9, 2026
FREDERICK, MD, – Cartesian Therapeutics, Inc., a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced a...CONTROLLED RELEASE - Precision in Every Dose: Advancing Controlled Release for Small Molecule Therapeutics June 8, 2026
Controlled release technologies are helping small molecule therapeutics deliver more consistent drug exposure, improve patient adherence, reduce dosing frequency, and support more precise treatment through advanced formulation and delivery strategies.
EXECUTIVE INTERVIEW - Intensity Therapeutics: Providing Cancer Patients With Treatments That Work October 7, 2025
Lew Bender, Founder and CEO of Intensity Therapeutics, discusses the company’s science, clinical program, the drug development process, and more.
Secarna Pharmaceuticals and Vect-Horus Announce Research Collaboration to Advance Systemic Delivery of RNA-Targeted Therapeutics for CNS Disorders July 10, 2025
Martinsried, Germany, and Marseille, France - Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of...OBI Pharma Enters ADC Collaboration With TegMine Therapeutics Utilizing GlycOBI & TegMiner Enabling Technologies June 6, 2025
OBI Pharma, Inc. and TegMine Therapeutics, Inc. have entered into an ADC-related Master Services Agreement (MSA). Under the terms of...PROTEIN BARCODING - Streamlining mRNA Therapeutic & Vaccine Development June 3, 2025
Meredith Carpenter, PhD, reviews how lipid nanoparticles have emerged as a powerful tool for delivery due to their low immunogenicity compared to viral vectors, along with their ability to encapsulate and protect nucleic acids and facilitate their entry into cells.
ALX Oncology Receives IND Clearance From FDA for a Novel EGFR-Targeted ADC April 7, 2025
ALX Oncology Holdings Inc. recently announced receipt of US FDA clearance for the Investigational New Drug (IND) application for ALX2004,...ADC PAYLOADS - Progress in Development of Camptothecin-Based ADC Therapeutics April 4, 2025
Paul Moore, PhD, Raffaele Colombo, PhD, and Jamie Rich, PhD, say the recent progress in research on novel camptothecin payloads highlights the potential for developing a new generation of ADCs that can overcome some of the limitations of first-generation therapies.
SPECIAL FEATURE - Analytical Testing – Diverse Demands & Therapies Require Diverse Analyses February 11, 2025
Contributor Cindy H. Dubin highlights how analytical testing has evolved to address diverse pharmaceutical therapeutics in research and development.
Lirum Therapeutics Presents Positive Data on Novel Clinical-Stage Targeted Therapy February 26, 2024
Lirum Therapeutics, Inc. recently announced today it presented positive data on LX-101, a novel clinical-stage targeted therapy directed to the...CordenPharma & pHLIP Announce Strategic Alliance to Develop pHLIP LNP Targeted Delivery Platform for RNA & Gene Therapies January 4, 2024
CordenPharma International and pHLIP, Inc. recently announce their strategic alliance to collaborate in developing and commercializing the pHLIP-LNP targeted delivery...LIPOSOMAL PEPTIDE THERAPEUTICS - Revolutionizing Oncology: Unleashing Innovative Strategies to Tackle Challenging, High-Value Drug Targets December 4, 2023
Natalia Zisman, Krishna Allamneni, PhD, and Stacy W. Blain, PhD, explain how targeting downstream signaling proteins offers a promising approach to effectively mitigate the emergence of drug resistance that precision oncology therapies leave behind.
Flashpoint Therapeutics Announces $10M Seed Financing to Pioneer Nanotechnology-Enabled Medicines October 26, 2023
Flashpoint Therapeutics recently announced $10M seed financing round led by Beta Lab, a leading deep tech venture capital firm headquartered...Shape(TX) Collaborates With Otsuka to Develop Novel AAV Gene Therapies for Ocular Diseases September 8, 2023
Shape(TX) and Otsuka Pharmaceutical Co., Ltd. recently announced a multi-target collaboration to develop intravitreally delivered adeno-associated viruses (AAVs) for ocular….
SiSaf & the University of Leipzig Partner to Develop Bio-Courier Targeted miRNA for the Treatment of Pancreatic Cancer March 2, 2023
SiSaf Ltd recently announced its collaboration with the University of Leipzig, Germany, to develop Bio-Courier targeted micro interfering RNAs (miRNA) for the treatment of….
VacV Biotherapeutics Emerges From Stealth Mode to Bring Ground-Breaking Cancer Immunotherapies to the Clinic October 26, 2022
VacV Biotherapeutics recently emerged from stealth mode to advance its promising pipeline of preclinical assets with best-in-class potential, toward the clinic…..
EXTRACELLULAR VESICLES - Engineering Extracellular Vesicles to Create Next-Generation Therapeutics October 3, 2022
David Lowe, PhD, Justin Hean, PhD, Dave Carter, PhD, and Antonin de Fougerolles, PhD, say EVs exhibit key properties that make them extremely attractive as therapeutics, particularly their safety profile and potential for low immunogenicity. In order to effectively unlock this potential, some key challenges remain, such as the development of EV product manufacture and characterization methodologies and rapid pharmacokinetics.
GENE THERAPY - Developing Affordable Point of Care CAR-T Therapies: Expanding Efficacy & Impact August 31, 2022
Rimas Orentas, PhD, and Boro Dropulić, PhD, MBA, believe the future belongs to those who will be able to innovate rapidly, maintain regulatory confidence, and drive down costs to make CAR-T cell and other engineered cell therapies available to all who would benefit.
